Thomas Brechenmacher
Rueil-malmaison, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
An enhanced mixture method for constructing gatekeeping procedures in clinical trials.
Journal: Journal of biopharmaceutical statistics
Published: December 15, 2017
Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of Everolimus.
Journal: Targeted oncology
Published: May 20, 2016
Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials.
Journal: Clinical genitourinary cancer
Published: November 29, 2015
Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 11, 2015
Safety of Everolimus in Patients Younger than 3 Years of Age: Results from EXIST-1, a Randomized, Controlled Clinical Trial.
Journal: The Journal of pediatrics
Published: August 17, 2015
Mixture-based gatekeeping procedures for multiplicity problems with multiple sequences of hypotheses.
Journal: Journal of biopharmaceutical statistics
Published: August 07, 2015
Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis.
Journal: British journal of clinical pharmacology
Published: March 26, 2015
The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: April 15, 2014
Showing 1-8 of 8
Last Updated: 09/26/2026